<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02982707</url>
  </required_header>
  <id_info>
    <org_study_id>CV010-013</org_study_id>
    <nct_id>NCT02982707</nct_id>
  </id_info>
  <brief_title>Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants</brief_title>
  <official_title>Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single oral dose of BMS-986177administered to subjects of mild hepatic impairment, moderate
      hepatic impairment and healthy matched subjects to evaluate pharmacokinetics, safety, and
      tolerability in these subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986177</measure>
    <time_frame>Up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-987177</measure>
    <time_frame>Up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the time the last quantifiable concentration (AUC(0-T)) of BMS-986177</measure>
    <time_frame>Up to 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to (AUC(0-72)) of BMS-986177</measure>
    <time_frame>Up to 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation</measure>
    <time_frame>Screening until 30 days after discontinuation of dosing or subject's participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical laboratory abnormalities</measure>
    <time_frame>Screening until 30 days after discontinuation of dosing or subject's participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in electrical activity of the heart measured by electrocardiogram (ECG)</measure>
    <time_frame>Screening until 30 days after discontinuation of dosing or subject's participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with vital sign abnormalities</measure>
    <time_frame>Screening until 30 days after discontinuation of dosing or subject's participation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Mild Hepatic Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are given a single dose of BMS-986177</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are given a single dose of BMS-986177</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Match Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are given a single dose of BMS-986177</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986177</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Mild Hepatic Subjects</arm_group_label>
    <arm_group_label>Moderate Hepatic Subjects</arm_group_label>
    <arm_group_label>Healthy Match Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women not of childbearing potential (WNOCBP) and males. Women must have documented
             proof they are not of childbearing potential

          -  BMI of 20.0 to 38.0 kg/m2, inclusive

          -  Hepatic subjects classified as Child-Pugh mild (Class A) or Child-Pugh moderate (Class
             B) who have had no significant change to disease status in past 6 months and are on
             stable treatment regimen

          -  Healthy subjects must not have clinically significant deviations from normal in
             medical history, physical exam, ECGs, vital signs or clinical lab values

        Exclusion Criteria:

          -  Evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or
             frequent unexplained bruising or thrombus formation

          -  Use of corticosteroids, nonsteroidal anti-inflammatory compounds, aspirin or other
             antiplatelet agents or anticoagulants within 2 weeks of dosing

          -  Healthy subjects must not have used tobacco or have a history of drug or alcohol abuse
             within the last 6 months

          -  Subjects must not have a current or recent (within 3 months) GI disease that increases
             participant risk of GI bleeding or interferes with absorption of the study drug

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information.Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Dilzer</last_name>
      <phone>305-817-2900</phone>
      <email>info@clinpharmmiami.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Lasseter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Bell</last_name>
      <email>dbell@ocrc.net</email>
    </contact>
    <investigator>
      <last_name>Thomas Marbury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Brown</last_name>
      <email>cbrown@txliver.com</email>
    </contact>
    <investigator>
      <last_name>Eric Lawitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/pages/home.aspx</url>
    <description>BMS Clinical Trial Education Resource</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

